Business
Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States
Natesto now covered as a Preferred Brand by leading national pharmacy benefits manager ENGLEWOOD, CO / ACCESSWIRE / June 3, 2020 / Aytu BioScience, Inc.
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Natesto now covered as a Preferred Brand by leading national pharmacy benefits manager ENGLEWOOD, CO / ACCESSWIRE / June 3, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the \"Company\"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that, as of July 1, 2020, Express Scripts, Inc., (\"Express Scripts\"), one of the leading pharmacy benefit managers (PBMs) in the United States, has elected to make Natesto® (testosterone nasal gel) a preferred brand on its National Preferred Drug List.Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, \"This improved formulary placement by Express Scripts is a significant development for Natesto enabling greater patient access in the U.S. The addition of Natesto as Preferred on the Express Scripts National Preferred formulary will enable significantly increased access to Natesto for the 13 million U.S. men diagnosed with hypogonadism.\"Express Scripts serves more than 3,000 clients covering 70 million lives, including approximately 9 million lives managed by Cigna HealthCare. Drugs listed on formulary as preferred brands have been evaluated by the pharmacy benefit manager from a therapeutic and value perspective. Preferred brand drugs may be available to patients at a lower co-pay or co-insurance than non-preferred brand drugs.Mr. Disbrow concluded, \"Natesto continues to be an important product for Aytu, and we believe that improving patient access will be an important growth driver for the Company going forward. We anticipate a significant increase in the number of men on therapy in the months ahead especially as our colleagues at Acerus prepare to launch their U.S. sales force to complement our commercial team.\"About Aytu BioScience, Inc.Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or \"Low T\"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 1...